FDA Determines Regulatory Review Period for FARYDAK Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for FARYDAK, a human drug product, in response to patent extension applications submitted to the U.S. Patent and Trademark Office (USPTO).